Kristin Wall

CETA Trade Negotiations 2011 - Drug Market Exclusivity in the EU and Canada
Jill Daley,Patrick E. Kierans,Kristin Wall, October 25, 2011
This briefing contributes to the current debate around IP rights for pharmaceuticals in Canada.

Federal Court Of Appeal Refuses to Set Aside Prohibition Order Following a Successful Impeachment Action
Jason C. Markwell,Kavita Ramamoorthy,Kristin Wall, July 28, 2011
In July 2009, Ratiopharm Inc. (Ratiopharm) impeached Canadian Patent No. 1,321,393 (393 Patent) pertaining to the Pfizer Canada Inc. (Pfizer) drug NORVASC®. Ratiopharm subsequently brought a motion to set aside an earlier prohibition order. The Federal Court of Appeal (FCA) dismissed...

Pharma In Brief - Validity of Data Protection Regulations Confirmed: Supreme Court of Canada Dismisses Application for Leave to Appeal by Generic Manufacturers
Jason C. Markwell,Kavita Ramamoorthy,Kristin Wall, July 27, 2011
On July 14, 2011, the Supreme Court of Canada dismissed two related applications for leave to appeal submitted by Apotex Inc. (Apotex) and the Canadian Generic Pharmaceutical Association (CGPA).